Innovus Pharmaceuticals Inc. (fka INNV)

[healthywelth]

Answer to SYD .....Team - here are the responses from Kevin. As I stated before, he is a class-act and a great professional and I have the utmost respect for him.
_____________________________________________________________________________________________
Syd,

Some of this would require divulging information which is not public, but here is what I can tell you.

1) At current growth rate of 29% quarter over quarter Innovus would have revenues in excess of $13 MM. Many of the partnerships and new products were not in place for all of Q1, but will be for the remainder of the year.

2) Agree this is a broad range and hopefully will be clarified in the future.

3) The operating expenses for 2016 were primarily due to the increase in non-cash stock-based compensation to consultants for services rendered and an increase in the amortization of intangible assets as a result of the acquisitions in 2016 and 2015. Many of these are not repeating expenses. Additionally gross margins have jumped dramatically since last year. Your assumptions on revenue necessary to break even and turn profitable may not be correct if you are utilizing all of 2016 as a guide to extrapolate expenses.

4) There are some cash expenses associated with the preparations and launch of Fluticare that were not there in 2016.

Kevin Holmes
Chesapeake Group